Arcutis Biotherapeutics, Inc. (ARQT) has a consensus analyst rating of Buy, based on 12 analysts covering the stock. Of those, 10 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for ARQT is $33.33, representing a +32.8% upside from the current price of $25.09. Price targets range from a low of $29.00 to a high of $37.00.
